How many 8-K filings has Bone Biologics Corp filed?

Bone Biologics Corp (BBLGW) has 21 8-K (Current Event Report) filings on record, spanning Jan 2024 to Sep 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Bone Biologics Corp 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Bone Biologics Corp 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Bone Biologics Corp (BBLGW) — 8-K Filings

All 8-K filings from Bone Biologics Corp. Browse 21 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (21)

Bone Biologics Corp Files 8-K — Sep 4, 2025 Risk: low
Bone Biologics Corporation filed an 8-K on September 4, 2025, reporting current information. The filing indicates the company's primary business is in orthopedi
Bone Biologics Corp Files 8-K with Material Agreements — Jun 30, 2025 Risk: medium
On June 27, 2025, Bone Biologics Corporation entered into a material definitive agreement. The company also reported other events and filed financial statements
Bone Biologics Files 8-K Report — Jun 26, 2025 Risk: low
On June 25, 2025, Bone Biologics Corporation filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
Bone Biologics Corp. Files 8-K on Security Holder Rights — Jun 6, 2025 Risk: medium
On June 5, 2025, Bone Biologics Corp. filed an 8-K report detailing material modifications to the rights of security holders and other events. The filing indica
Bone Biologics Corp. Files 8-K on Officer/Director Changes — May 30, 2025 Risk: medium
Bone Biologics Corp. filed an 8-K on May 30, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain of
Bone Biologics Faces Delisting Concerns — Apr 11, 2025 Risk: high
Bone Biologics Corporation filed an 8-K on April 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event re
Bone Biologics Files 8-K on Shareholder Nominations — Apr 1, 2025 Risk: medium
Bone Biologics Corporation filed an 8-K on April 1, 2025, reporting an event on March 26, 2025, related to shareholder nominations under Exchange Act Rule 14a-1
Bone Biologics Corp Files 8-K — Dec 13, 2024 Risk: low
On December 13, 2024, Bone Biologics Corporation filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine upda
Bone Biologics Corp Files 8-K on Officer/Director Changes — Oct 21, 2024 Risk: medium
Bone Biologics Corporation filed an 8-K on October 21, 2024, reporting events as of October 16, 2024. The filing pertains to the departure of directors or certa
Bone Biologics Corp Reports Officer/Director Changes — Oct 4, 2024 Risk: medium
Bone Biologics Corporation filed an 8-K on October 4, 2024, reporting events as of October 1, 2024. The filing pertains to the departure of directors or certain
Bone Biologics Corp Files 8-K for Material Definitive Agreement — Sep 27, 2024 Risk: medium
On September 27, 2024, Bone Biologics Corporation entered into a material definitive agreement. The filing does not disclose specific details of the agreement,
Bone Biologics Corp Files 8-K on Security Holder Vote — Sep 19, 2024 Risk: low
Bone Biologics Corporation filed an 8-K on September 19, 2024, reporting on matters submitted to a vote of security holders on September 17, 2024. The filing de
Bone Biologics Corp Files 8-K for Equity Sales — Aug 2, 2024 Risk: medium
On August 1, 2024, Bone Biologics Corporation entered into a material definitive agreement related to the sale of its common stock and warrants. The company als
Bone Biologics Files 8-K: Regulation FD & Exhibits — Jun 20, 2024 Risk: low
On June 20, 2024, Bone Biologics Corporation filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the filing of Financial Statements
Bone Biologics Elects New Directors, Adjusts Executive Pay — Mar 15, 2024 Risk: medium
Bone Biologics Corporation announced on March 12, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company el
Bone Biologics Corp Files 8-K: Material Definitive Agreement — Mar 6, 2024 Risk: medium
On March 4, 2024, Bone Biologics Corporation entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company, headq
Bone Biologics Files 8-K Report — Mar 1, 2024 Risk: low
On March 1, 2024, Bone Biologics Corporation filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not contain s
Bone Biologics Files 8-K for Undisclosed 'Other Event' — Jan 12, 2024
Bone Biologics Corp. filed an 8-K on January 12, 2024, reporting an "Other Event" that occurred on January 10, 2024. While the filing itself is brief and doesn'
Bone Biologics Confirms Nasdaq Listing for Common Stock & Warrants — Jan 11, 2024
Bone Biologics Corp. filed an 8-K on January 11, 2024, reporting an event that occurred on January 8, 2024. This filing primarily serves to update the company's
Bone Biologics Files Routine 8-K on Jan 9 Event — Jan 10, 2024
Bone Biologics Corp. filed an 8-K on January 10, 2024, reporting an event that occurred on January 9, 2024. This filing is a standard current report and does no
Bone Biologics Files Routine 8-K; No Major New Events Reported — Jan 2, 2024
Bone Biologics Corp. (BBLG) filed an 8-K on January 2, 2024, reporting that the earliest event occurred on December 27, 2023. This filing is a standard current

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX